SHALLCROSS STEVEN A (CEO and CFO) purchased 22.7% of their position (25K shares) of THERIVA BIOLOGICS, INC. on the open market
Open‑market purchase worth $18.7K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 1/23/2023ACC: 0001104659-23-005546
DirectorOfficer· CEO and CFO
Since Dec 2018
+25K
Net shares
Net buyer
$18.7K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
25K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+25K
Price / share
$0.75
Trade value
$18.70K
% of position
22.7%
1/20/2023
110K→135K
Total
Net shares
+25K
Net value
$18.70K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/20/2023 | P · Purchase | +25K | $0.75 | $18.70K | 22.7% | 110K | 135K |
| Total | +25K | $18.70K | ||||||
Derivative Transactions0
No derivative transactions reported